Amidst the continued struggle to treat non-small-cell lung cancer, a new study led by Stanford University scientists suggests that a patient's response to immunotherapy may hinge on how immune cells ...

While the approval is a historic event for the BiTE drug class in solid tumours, the market share opportunity is restricted ...

Science in dialogue – leading minds gathered by the Jung Foundation. Now available to stream on YouTube.

Tübingen achieves remarkable success and has good chance of maintaining its University of Excellence title – Top research in three areas to be sustained from other sources of support ...

One of the key advantages of CAR T-cell therapy is that it does not cause the side-effects associated with chemotherapy and ...

Energy sector pushes ASX 0.15pc higher US court has ruled Trump’s Liberation Day and fentanyl tariffs are unlawful Steel, ...

The findings provide insight into which patients may have favorable or inferior responses to immunotherapy for small cell ...

Christopher Polk/Billboard via Getty The Real Housewives of Beverly Hills alum said that while that means her "body is responding to everything," she does need to live on immunotherapy for the ...

The research focuses on immunotherapy. Experts said this treatment could mean fewer surgeries, less chemotherapy, and more hope for patients with some early-stage gastrointestinal cancers.

They have also developed an experimental immunotherapy capable of reversing this process and restoring cellular energy production. The study, recently published in the Journal of Lipid Research ...

“I'm actually doing great,” Mellencamp told PEOPLE. “I had immunotherapy two days ago and they did another round of scans and they said all my tumors are continuing to shrink, so I'm feeling ...